Investigation of immune and haematopoietic disorders

Lead Research Organisation: MRC Laboratory of Molecular Biology

Abstract

The World Health Organisation estimates that in the region of 300 million people worldwide now suffer from asthma.
Allergic asthma is caused by an abnormal reaction to a variety of environmental agents, called allergens. This leads to long-term lung inflammation and an over-responsiveness of the airways. As the airways become narrowed and irritated, coughing, wheezing and shortness of breath occur.
The body is normally protected by its immune system, but during asthma it becomes inappropriately activated by allergens such as pollen and dust. We are trying to understand how the immune system is being controlled and identify points at which we may be able to block it and thereby improve asthma symptoms.
Cells of the immune system communicate by sending out protein messengers (called interleukins ) that are received by other cells and cause them to switch on specific functions – for example to start producing mucus in the lung in response to irritation. We have discovered a new immune cell (ILC2) that plays a key role in receiving and sending out messages during asthma-like disease.
We have shown using mouse asthma models that blocking the action of interleukin-25 (IL-25) inhibits asthma-like responses. We have gone on to produce antibodies that target either IL-25 or its receptor, and these are being developed as potential therapeutics.

Technical Summary

Allergic asthma is characterised by uncontrollable airways hyperresponsiveness (AHR) induced by a variety of provocative stimuli and is associated with type-2 inflammatory infiltrates into the lungs. The number of sufferers has increased dramatically over recent decades and the World Health Organisation estimates that in the region of 300 million people worldwide suffer from this disorder.
Using transgenic mouse models we have characterised fundamental inter-dependent roles for the type-2 cytokines interleukin-4 (IL-4), IL-5, IL-9 and IL-13 as mediators of asthma and allergy. More recently we have focussed on characterising critical molecules that initiate the type-2 response. These include IL-25 and IL-33. IL-25 is a member of the IL-17 family of cytokines and we have demonstrated an important role for IL-25 in protective immunity to infection and uncovered a critical role for IL-25 in airways hyperresponsiveness and inflammation. We developed monoclonal antibodies that block the interaction of IL-25 with its receptor, and administration of this antibody prevents airways hyperresponsiveness in a mouse model of allergic asthma. These antibodies have been humanised and licenced for further development as therapeutics.
Using Il13-eGFP reporter mice, we discovered type-2 innate lymphoid cells (ILC2) and demonstrated that they are the predominant early source of the IL-13 critical for inducing expulsion of the helminth parasite, Nippostrongylus brasiliensis, following infection. ILC2 also expand in experimental models of asthma, where they represent an important source of type-2 cytokines. Our recent studies have indicated that ILC2 interact with dendritic cells and Th2 cells to potentiate type-2 immunity. We have shown that these type-2 ILCs develop from common lymphoid progenitors under signals from IL-7 and IL-33 and Notch. We have gone on to show that the transcription factors RORa and Bcl11b play important roles in ILC2 development. Furthermore, using a novel panel of transcription factor reporter mice we have defined a new model for ILC progenitor development in the bone marrow.

Organisations

Publications

10 25 50
 
Description BBSRC working strategy advisory panel
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description DFG panel - clusters of excellence in Immunology, Virology and Microbiology
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description Meeting with Head of Office of Life Sciences to discuss the case for supporting science
Geographic Reach National 
Policy Influence Type Implementation circular/rapid advice/letter to e.g. Ministry of Health
 
Description Meeting with Stuart Agnew MEP to advise on EU parliamentary debate on animal use in scientific research
Geographic Reach Europe 
Policy Influence Type Implementation circular/rapid advice/letter to e.g. Ministry of Health
 
Description Participation in a advisory committee - DFG panel - clusters of excellence in Immunology, Virology and Microbiology (2018)
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description A*Star Singapore National Science Scholarship (Hwang)
Amount $155,000 (SGD)
Organisation Agency for Science, Technology and Research (A*STAR) 
Sector Public
Country Singapore
Start 10/2010 
End 09/2015
 
Description AZ/LMB Blue Skies Funding (Kozik)
Amount £200,000 (GBP)
Funding ID BSF34 
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 02/2019 
End 02/2021
 
Description American Asthma Foundation Programme grant
Amount £500,000 (GBP)
Organisation American Asthma Foundation 
Sector Charity/Non Profit
Country United States
Start 07/2010 
End 06/2014
 
Description Asthma UK Project Grant
Amount £140,826 (GBP)
Funding ID 07/001 
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2008 
End 04/2010
 
Description AstraZeneca/LMB Blue Skies Initiative
Amount £330,162 (GBP)
Organisation AstraZeneca 
Department Research and Development AstraZeneca
Sector Private
Country United Kingdom
Start 05/2015 
End 04/2018
 
Description Banting Fellowship
Amount $140,000 (CAD)
Funding ID 201211BPF-293444-193128 
Organisation Canadian Institutes of Health Research 
Sector Public
Country Canada
Start 04/2013 
End 03/2015
 
Description César Milstein Memorial studentship of the Darwin Trust, Edinburgh
Amount £72,000 (GBP)
Organisation British Society for the History of Science (BSHS) 
Department Darwin Trust of Edinburgh
Sector Academic/University
Country United Kingdom
Start 10/2006 
End 09/2009
 
Description Commercial funding
Amount $1,473,000 (USD)
Organisation Johnson & Johnson 
Department Janssen Pharmaceuticals
Sector Private
Country United States
Start 06/2013 
End 05/2016
 
Description Commercial funds
Amount $387,000 (USD)
Organisation Johnson & Johnson 
Department Janssen Pharmaceuticals
Sector Private
Country United States
Start 01/2013 
End 12/2016
 
Description Croucher Cambridge International Scholarship
Amount £123,312 (GBP)
Organisation The Croucher Foundation 
Sector Charity/Non Profit
Country Hong Kong
Start 10/2016 
End 09/2020
 
Description GSK Agreement 100042097
Amount £296,000 (GBP)
Funding ID 100042097 
Organisation GlaxoSmithKline (GSK) 
Department GlaxoSmithKline Medicines Research Centre
Sector Private
Country United Kingdom
Start 08/2015 
End 07/2017
 
Description Leukaemia and Lymphoma Research project grant
Amount £163,450 (GBP)
Organisation Leukaemia and Lymphoma Research 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2011 
End 12/2013
 
Description MRCT Development Gap Funding
Amount £116,933 (GBP)
Organisation MRC-Technology 
Sector Academic/University
Country United Kingdom
Start 07/2008 
End 06/2010
 
Description MRCT Development Gap Funding
Amount £62,320 (GBP)
Organisation MRC-Technology 
Sector Academic/University
Country United Kingdom
Start 07/2007 
End 06/2008
 
Description Sir Henry Wellcome Postdoctoral Fellowship - Kozik
Amount £42,006 (GBP)
Funding ID 101578/C/13/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 05/2018
 
Description Wellcome Trust Senior Investigator
Amount £2,079,643 (GBP)
Funding ID 100963/Z/12/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2013 
End 09/2019
 
Title IL-13 reporter mice 
Description Insertion of fluorescent reporter into IL-13 gene 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2010 
Provided To Others? Yes  
Impact Tracking IL-13 producing nuocytes in experimental asthma 
 
Title IL-17BR-deficient mice 
Description IL-17BR-deficient mice 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2010 
Provided To Others? Yes  
Impact The functional characterisation of a new immune cells - the nuocyte. 
 
Title IL-33 citrine reporter mice 
Description Knockin mouse in which the citrine fluorescence gene has been inserted into the IL-33 gene. This allows researchers to visualise IL-33 gene expression during infection and disease models. 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2012 
Provided To Others? Yes  
Impact publication of novel data 
 
Title Interleukin-25-deficient mice 
Description Mice lacking the cytokine IL-25 
Type Of Material Technology assay or reagent 
Year Produced 2007 
Provided To Others? Yes  
Impact These mice have been supplied to several laboratories around the world for asthma research. 
 
Title Monoclonal antibody against IL-17BR 
Description Monoclonal antibody against IL-17BR 
Type Of Material Antibody 
Year Produced 2009 
Provided To Others? Yes  
Impact This antibody is able to inhibit the biological activity of IL-25 in experimental asthma 
 
Title Monoclonal antibody against IL-25 
Description Monoclonal antibody against IL-25 
Type Of Material Antibody 
Year Produced 2006 
Provided To Others? Yes  
Impact This antibody has been licensed for commercial development as a therapeutic. 
 
Title Rora-flox ILC2 deletion mice 
Description development of mice in which ILC2 are absent 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2014 
Provided To Others? Yes  
Impact The discovery of roles ILC2 in adaptive immunity. 
 
Title SIGN-R1-deficient mice 
Description Mice lacking SIGN-R1 molecule 
Type Of Material Technology assay or reagent 
Year Produced 2006 
Provided To Others? Yes  
Impact Used in the analysis of infection models 
 
Title T1/ST2-deficient (IL-33 receptor) mice 
Description Mice lacking T1/ST2 (IL-33 receptor) 
Type Of Material Technology assay or reagent 
Year Produced 2006 
Provided To Others? Yes  
Impact Used in asthma and immunology research. 
 
Title iCOS-T mice 
Description Development of mice in which ILC2 can be deleted temporally using diphtheria toxin 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2014 
Provided To Others? Yes  
Impact Discovery of a role for ILC2 in adaptive immune activation 
 
Title type 2 cytokine-deficient mice 
Description Mice with combined deficiencies in type-2 cytokines 
Type Of Material Technology assay or reagent 
Year Produced 2006 
Provided To Others? Yes  
Impact Allow clear demarcation of involvement of type-2 cytokine-independent immune pathways in asthma and immunology. 
 
Description 5q 
Organisation Oxford University Hospitals NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Generation of mouse model of human 5q- disease
Collaborator Contribution Pre-publication data
Impact 20360478 19966810 20733155
 
Description Amphiregulin - EGFR - Zaiss 
Organisation University of Edinburgh
Department Institute of Immunology and Infection Research
Country United Kingdom 
Sector Academic/University 
PI Contribution Transgenic mouse strains, know-how, intellectual input
Collaborator Contribution EGFR signalling
Impact 29045902
Start Year 2015
 
Description Atheroslerosis - Mallat 
Organisation University of Cambridge
Department Department of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Transgenic mouse strains, know-how, intellectual input
Collaborator Contribution Experience with atheroslerosis models
Impact 28589929
Start Year 2014
 
Description COPD - Hansbro (2014- ongoing) 
Organisation University of Newcastle
Country Australia 
Sector Academic/University 
PI Contribution Reagents, experiments, know-how
Collaborator Contribution Know-how
Impact PMID: 30260499
Start Year 2014
 
Description Chitin and ILC2 
Organisation University of California, San Francisco
Country United States 
Sector Academic/University 
PI Contribution intellectual, reagents
Collaborator Contribution intellectual, facilities
Impact PMID: 24613091
Start Year 2011
 
Description Dendritic cells (MacDonald) 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution Intellectual, reagents, facilities
Collaborator Contribution Intellectual, reagents, facilities
Impact PMID: 25908537
Start Year 2011
 
Description FALC ILCs (Caamano) 
Organisation University of Birmingham
Department School of Immunity and Infection
Country United Kingdom 
Sector Academic/University 
PI Contribution Intellectual, reagents
Collaborator Contribution Intellectual, reagents
Impact PMID: 26147686
Start Year 2011
 
Description Graf in brain macrophages 
Organisation Medical Research Council (MRC)
Department MRC Laboratory of Molecular Biology (LMB)
Country United Kingdom 
Sector Public 
PI Contribution Generation of gene-deficient mice and provision of experimental help and expertise
Collaborator Contribution Intellectual input. Facilities.
Impact PMID 25189622
Start Year 2006
 
Description Helminth expulsion - Maizels 2014 - 19 
Organisation University of Glasgow
Department Institute of Infection, Immunity and Inflammation
Country United Kingdom 
Sector Academic/University 
PI Contribution Reagents and know-how
Collaborator Contribution Know-how
Impact PMID: 30238872
Start Year 2014
 
Description Helminth infection 
Organisation Trinity College Dublin
Country Ireland 
Sector Academic/University 
PI Contribution Transgenic mouse models, intellectual input
Collaborator Contribution Technical help with parasite models
Impact Publications 17407196 17372014 16606668 16365404 20130211 18981244 28615416 28747424
 
Description IL-13 and BOS 
Organisation University of Michigan
Country United States 
Sector Academic/University 
PI Contribution Reagents and scientific discussion
Collaborator Contribution Unpublished data
Impact 16816360
 
Description IL-13 and Cryptococcus 
Organisation Charité - University of Medicine Berlin
Department Department of Neuropathology
Country Germany 
Sector Academic/University 
PI Contribution Reagents and scientific discussion
Collaborator Contribution Unpublished data
Impact 17911623 19147811
 
Description IL-13 and Cryptococcus 
Organisation University of Leipzig
Country Germany 
Sector Academic/University 
PI Contribution Reagents and scientific discussion
Collaborator Contribution Unpublished data
Impact 17911623 19147811
 
Description IL-13 and mammary development 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Reagents and scientific discussion
Collaborator Contribution Unpublished data
Impact 17611223
Start Year 2006
 
Description IL-13 and periostin 
Organisation Gifu Pharmaceutical University
Country Japan 
Sector Academic/University 
PI Contribution Reagents and scientific discussion
Collaborator Contribution Unpublished data
Impact 16815144
 
Description IL-13 in asthma 
Organisation Harvard University
Department Division of Immunology
Country United States 
Sector Academic/University 
PI Contribution Reagents and scientific discussions
Impact 19815118
 
Description IL-13 in glucose metabolism 
Organisation Harvard University
Department Harvard T.H. Chan School of Public Health
Country United States 
Sector Academic/University 
PI Contribution Reagents, and assessing the role of ILC2
Collaborator Contribution discovery of a role for IL-13 in glucose production
Impact PMID: 23257358
Start Year 2012
 
Description IL-13 in tuberculosis 
Organisation Borstel Research Centre
Department Infection Immunology
Country Germany 
Sector Academic/University 
PI Contribution Reagents, intellectual input
Collaborator Contribution Facilities, intellectual input
Impact PMID: 24979482
Start Year 2008
 
Description IL-13 interaction with IL-9 
Organisation Catholic University of Louvain
Country Belgium 
Sector Academic/University 
PI Contribution Reagents and scientific discussion
Collaborator Contribution Unpublished data
Impact 17312173, 19342650
 
Description IL-25 
Organisation Janssen Biotech, Inc.
Country United States 
Sector Private 
PI Contribution reagents and unpublished data
Collaborator Contribution reagents
Impact 20200518
Start Year 2009
 
Description IL-25 Th2 polyps - Till 
Organisation King's College London
Department Division of Asthma, Allergy and Lung Biology
Country United Kingdom 
Sector Academic/University 
PI Contribution Reagents, expertise
Collaborator Contribution Reagents, expertise
Impact PMID: 26684290
Start Year 2012
 
Description IL-25 feedback and worms 
Organisation Cleveland Clinic
Department Department of Allergy and Clinical Immunology
Country United States 
Sector Public 
PI Contribution reagents, experiments, manuscript editing
Collaborator Contribution unpublished data
Impact Manuscript
Start Year 2010
 
Description IL-33 
Organisation University of Glasgow
Department Institute of Infection, Immunity and Inflammation
Country United Kingdom 
Sector Academic/University 
PI Contribution Mouse strains and tissues. Gene targeting.
Collaborator Contribution Data on IL-33
Impact Publications 18802081 18667700 17853410 19506243 20139274 20473304 20634488
 
Description IL-33 alternaria and ILC2 
Organisation Mayo Clinic
Department Division of Allergic Diseases
Country United States 
Sector Charity/Non Profit 
PI Contribution reagents and unpublished data, suggested experiments, editing manuscript
Collaborator Contribution unpublished data
Impact manuscript PMID: 25015831
Start Year 2010
 
Description IL-33 and ILC in fibrosis 
Organisation Friedrich-Alexander University Erlangen-Nuremberg
Country Germany 
Sector Academic/University 
PI Contribution Reagents and know-how, and manuscript writing
Collaborator Contribution New knowledge on the roles of IL-33 in fibrosis
Impact PMID: 23954132
Start Year 2011
 
Description IL-33 and IgE 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Reagents required to complete the study
Collaborator Contribution Unpublished results
Impact Manuscript
 
Description IL-33 and LPS 
Organisation University Paris Sud
Department Institute of Biochemistry and Molecular and Cellular Biophysics
Country France 
Sector Academic/University 
PI Contribution Reagents and scientific discussions
Impact 19553541
Start Year 2008
 
Description IL-33 and Toxoplasma 
Organisation University of Strathclyde
Department Strathclyde Institute of Pharmacy & Biomedical Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Reagents and scientific discussions
Impact 19950183
 
Description IL-33 and leishmania 
Organisation Institute for Research on Health in the Working Environment (IRSET)
Country France 
Sector Academic/University 
PI Contribution New information on the role of IL-33 in infection
Collaborator Contribution Reagents and information
Impact PMID: 24045639
Start Year 2011
 
Description IL-33 and nuocytes in asthma and influenza 
Organisation Boston Children's Hospital
Country United States 
Sector Hospitals 
PI Contribution Unpublished data, reagents and suggested experiments
Collaborator Contribution Unpublished data
Impact Two manuscript
Start Year 2010
 
Description IL-33 at birth - Knapp 
Organisation Austrian Academy of Sciences
Department Research Centre for Molecular Medicine
Country Austria 
Sector Academic/University 
PI Contribution Expertise, reagents, hosting and training
Collaborator Contribution Expertise, intellectual contributions.
Impact PMID: 28228256
Start Year 2012
 
Description IL-33 protein 
Organisation University of Maryland
Department Division of Rheumatology & Clinical Immunology
Country United States 
Sector Academic/University 
PI Contribution Reagents, unpublished data, manuscript editing
Collaborator Contribution Unpublished data
Impact Manuscript
Start Year 2010
 
Description IL-9 and food allergy 
Organisation University of Cincinnati
Country United States 
Sector Academic/University 
PI Contribution Reagents and scientific discussion
Collaborator Contribution Unpublished data
Impact 18378796
Start Year 2006
 
Description IL-9/Th2 and STAT3 - Kaplan 
Organisation Indiana University
Department School of Medicine
Country United States 
Sector Academic/University 
PI Contribution expertise, intellectual input, reagents
Collaborator Contribution expertise, intellectual input, reagents
Impact PMID: 28137893
Start Year 2014
 
Description ILC2 GVHD - Serody 
Organisation University of North Carolina at Chapel Hill
Country United States 
Sector Academic/University 
PI Contribution Transgenic mouse strains, intellectual input
Collaborator Contribution Experience with GVHD models
Impact 28375154
Start Year 2014
 
Description ILC2 fibrosis and obesity 
Organisation Trinity College Dublin
Country Ireland 
Sector Academic/University 
PI Contribution intellectual, reagents, facilities
Collaborator Contribution intellectual, reagents, facilities
Impact PMID: 24166975 PMID: 24344271 PMID: 26490658
 
Description ILC2 lung virus 
Organisation Boston Children's Hospital
Country United States 
Sector Hospitals 
PI Contribution reagents and unpublished data, suggested experiments, editing manuscript
Collaborator Contribution unpublished data
Impact manuscript
 
Description ILK-25/IL-33 nasal polyps (Cousins/Till) 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Reagents, know-how
Collaborator Contribution Access to human tissue samples
Impact PMID: 26684290
Start Year 2011
 
Description PD1 in ILC2 - Liu 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution expertise, intellectual input, reagents
Collaborator Contribution expertise, intellectual input, reagents
Impact PMID: 27749818
Start Year 2011
 
Description RSV and ILC2 - Peebles 
Organisation Vanderbilt University
Department Vanderbilt Medical Center
Country United States 
Sector Academic/University 
PI Contribution expertise, intellectual input, reagents
Collaborator Contribution expertise, intellectual input, reagents
Impact PMID: 27156176
Start Year 2013
 
Description SBDS 
Organisation University of Cambridge
Department Department of Haematology
Country United Kingdom 
Sector Academic/University 
PI Contribution Generation of reagents, experimental input, unpublished data
Collaborator Contribution Unpublished data
Impact Manuscript
Start Year 2006
 
Description SHP-1 and IL-13 
Organisation Johns Hopkins Medicine
Department Division of Allergy and Clinical Immunology
Country United States 
Sector Academic/University 
PI Contribution Reagents and scientific discussions
Impact 18952567
Start Year 2007
 
Description SIGNR1 and TB 
Organisation University of Amsterdam
Country Netherlands 
Sector Academic/University 
PI Contribution Reagents and scientific discussion
Collaborator Contribution Unpublished data
Impact 17224292, 18802081
 
Description SOCS induced IL-13 
Organisation Research Institute for Diseases of the Chest Kyushi
Country Japan 
Sector Academic/University 
PI Contribution Reagents and scientific discussions
Impact 19299500
Start Year 2006
 
Description ST2 and heart inflammation 
Organisation Harvard University
Department Harvard Medical School
Country United States 
Sector Academic/University 
PI Contribution Reagents and scientific discussion
Collaborator Contribution Unpublished data
Impact 17492053
 
Description ST2 in pancreatitis 
Organisation University Libre Bruxelles (Université Libre de Bruxelles ULB)
Department Laboratory of Experimental Gastroenterology, Erasme Hospital
Country Belgium 
Sector Academic/University 
PI Contribution reagents, unpublished data, manuscript editing
Collaborator Contribution unpublished data
Impact Manuscript
Start Year 2009
 
Description Single cell RNAseq - Teichmann 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Reagents, expertise, intellectual input
Collaborator Contribution Reagents, expertise, intellectual input
Impact PMID: 27176874 PMID: 30355343
Start Year 2010
 
Description T-bet and ILC3 
Organisation The Walter and Eliza Hall Institute of Medical Research (WEHI)
Country Australia 
Sector Academic/University 
PI Contribution experiments on ILC2
Collaborator Contribution Identification of Tbet in ILC3 deevlopment
Impact PMID: 23455676
Start Year 2011
 
Description TL1A and ILC2 
Organisation National Institutes of Health (NIH)
Country United States 
Sector Public 
PI Contribution Intellectual, reagents, facilities
Collaborator Contribution Intellectual, reagents, facilities
Impact PMID: 24368564
Start Year 2011
 
Description Th9 cells in epithelial cells 
Organisation Friedrich-Alexander University Erlangen-Nuremberg
Country Germany 
Sector Academic/University 
PI Contribution Intellectual, reagents, facilities
Collaborator Contribution Intellectual, reagents, facilities
Impact PMID: 24908389 PMID: 25838986 28714991
Start Year 2013
 
Description Type-2 cytokines and GVHD 
Organisation University of Michigan
Country United States 
Sector Academic/University 
PI Contribution Reagents and scientific discussion
Collaborator Contribution Unpublished data
Impact 18410989
Start Year 2006
 
Description Type-2 cytokines and asthma 
Organisation Imperial College London
Department National Heart & Lung Institute (NHLI)
Country United Kingdom 
Sector Academic/University 
PI Contribution Reagents and scientific discussion
Collaborator Contribution Unpublished data
Impact 17883722 18417511
 
Description helminth secretions and ILC2 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Intellectual, reagents, facilities
Collaborator Contribution Intellectual, reagents, facilities
Impact PMID: 24496315
Start Year 2012
 
Description human skin ILC2 - Ogg 
Organisation University of Oxford
Department Weatherall Institute of Molecular Medicine (WIMM)
Country United Kingdom 
Sector Public 
PI Contribution Intellectual, reagents, equipment
Collaborator Contribution Intellectual, reagents, equipment
Impact PMID: 24323357 PMID: 24388011 PMID: 26582946 29273672 26299987
Start Year 2012
 
Description il33 and il25 - airway contractility 
Organisation Queen's Medical Centre
Country United Kingdom 
Sector Hospitals 
PI Contribution Reagents, exptl design etc
Collaborator Contribution Contractility assay
Impact PMID: 23810766
Start Year 2008
 
Description single cell rna Th2 
Organisation EMBL European Bioinformatics Institute (EMBL - EBI)
Country United Kingdom 
Sector Academic/University 
PI Contribution intellectual, facilities, reagents
Collaborator Contribution intellectual, facilities,
Impact PMID: 24813893
Start Year 2010
 
Description tumour pgd2 and ILC2 - Jandus/Donath 
Organisation University of Lausanne
Country Switzerland 
Sector Academic/University 
PI Contribution Transgenic strains, know-how, intellectual input
Collaborator Contribution Tumour models and immuno-suppressive monocytes
Impact 28928446
Start Year 2015
 
Title Anti-IL-25 
Description An antibody that blocks the bioactivity of IL-25. This has now been humanised and licensed for development. 
IP Reference EP2144934 
Protection Patent granted
Year Protection Granted 2010
Licensed Yes
Impact Humanised monoclonal antibody to the IL-25 which has potential as a therapeutic agent for the treatment of allergic asthma. Patent granted
 
Title Licencing IL-17BR-deficient mouse 
Description IL-17BR-deficient mouse 
IP Reference  
Protection Protection not required
Year Protection Granted 2016
Licensed Yes
Impact N/A
 
Title Licencing IL-4/13-deficient mouse 
Description IL-4/13-deficient mouse 
IP Reference  
Protection Protection not required
Year Protection Granted 2016
Licensed Yes
Impact N/A
 
Title Licencing ST2-deficient mouse 
Description Licencing ST2-deficient mouse 
IP Reference  
Protection Protection not required
Year Protection Granted 2016
Licensed Yes
Impact N/A
 
Title Anti-IL-25 antibody 
Description We have developed an antibody that specifically blocks the biological activity of IL-25, preventing many of the features of asthma in mouse models. The antibody has been humanised in collaboration with MRCT. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Initial development
Year Development Stage Completed 2008
Development Status Under active development/distribution
Impact This antibody has been licensed for development as a therapeutic. 
 
Description ANR Scientific Evaluation Committee (CE12, Genetics, genomics, gene expression, regulator RNAs), France - Cristina Rada 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Cristina Rada was a member of the expert panel assessing research at the Frendch National Research Agency (ANR) which provides funding for project-based research in all fields of science - for both basic and applied research - to public research organisations and universities, as well as to private companies (including SMEs). Employing a method based on competitive peer reviews compliant with international standards, ANR provides the scientific community with instruments and programmes promoting creativity and openness, and stimulate new ideas and partnerships, particularly between academia and industry. Its activity also contributes to enhancing the competitiveness and the influence of French research in Europe and across the world.
Since 2010, ANR has also been the lead manager of the Investments for the Future programme in the field of higher education and research, in charge of project selection, funding and monitoring.
Year(s) Of Engagement Activity 2016
URL http://www.agence-nationale-recherche.fr/en/about-anr/about-the-french-national-research-agency/
 
Description Biomedical opportunities in deep sequencing of immunological repertoires EMBL-EBI Workshop, HInxton - Cristina Rada 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Cristina Rada gave a presentation at the EMBL-EBI Industry workshop on Biomedical opportunities in deep sequencing of immunological repertoires. As well as the audience the workshop was linked to online participants. Debate and discussion followed. The workshop series is part of EBI's industry programme which links industry and academia.
Year(s) Of Engagement Activity 2016
URL http://www.ebi.ac.uk/industry
 
Description Editor of LMB Brochure 2016 - Cristina Rada 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Cristina Rada edited the 2016 LMB brochure which is the LMB's main printed communication tool for the general public. It is also used for recruitment of PhD students and providing information for academic visitors, policymakers and general visitors.
Year(s) Of Engagement Activity 2016
 
Description HCERES President of the Evaluation Committee of CNRS Unit, Limoges, France - Cristina Rada 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Cristina Rada was the Chair of a Site Visit Committee at CNRS Unit, Limoges, France for their evaluation of research and teaching in immunology.
Year(s) Of Engagement Activity 2016
URL http://www.hceres.com/Evaluation-procedures/List-of-experts-who-have-taken-part-in-an-evaluation
 
Description Hosting school students 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact The pupils have been highly enthusiastic and we are now taking three students per year.

For the past 3 years we have hosted GCSE and pre-A level students to give them experience of lab-based science. We have received considerable impact from the individuals and they have been able to ask for information on university courses and careers.
Year(s) Of Engagement Activity 2012,2013,2014
 
Description IAT meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact 150 animal technicians attended the talk on transgenics in asthma research at the regional IAT meeting. This generated discussion about the contribution of technicians in such projects.

Excellent feedback from the audience
Year(s) Of Engagement Activity 2011
 
Description LMB Open Day 2017 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Worms and sneezes - displays and interactive activities with explanations by McKenzie group scientists as part of wider LMB Open Day in June 2017.
Year(s) Of Engagement Activity 2017
 
Description Non-scientist seminar 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Seminar aimed at highlighting research on asthma to general public and MRC non-scientific support staff. Generated discussion and questions about new potential therapeutics in asthma.

N/A
Year(s) Of Engagement Activity 2011
 
Description Sawston Village College visit to Royal Society Exhibition by Cristina Rada 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Taking up to 20 GSCE science students to the annual Royal Society Summer Exhibition in London. This is to encourage students to take A level science subjects and the excite their curiosity for scientific learning.
Year(s) Of Engagement Activity 2016
 
Description School visit to the Royal Society Summer Exhibition Cristina Rada 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact 16 pupils from 15-16 years of age from STEM subjects chaperoned visit to Royal Society Summer Exhibition.
Year(s) Of Engagement Activity 2018
 
Description Seminar at King's College London - Cristina Rada 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Cristina Rada was invited to give a seminar to scientific colleagues at King's college, London. Audience was a mixture of postdocs, students and senior scientists. Follwed by debate and discussions.
Year(s) Of Engagement Activity 2016
 
Description Seminar at Saarbruken University, Germany - Cristina Rada 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Cristina Rada was invited to give a seminar to scientific colleagues at Saarbrueken University. Audience was a mixture of postdocs, students and senior scientists. Follwed by debate and discussions.
Year(s) Of Engagement Activity 2016
 
Description Seminar, Institute Curie, Paris, France - Cristina Rada 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Cristina Rada was invited to give a seminar to scientific colleagues at Institut Curie. Audience was a mixture of postdocs, students and senior scientists. Follwed by debate and discussions.
Year(s) Of Engagement Activity 2016
 
Description Speaker 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Health professionals
Results and Impact Presentation to clinicians at the European Respiratory Society on the therapeutic potential of blocking IL-25

None as yet
Year(s) Of Engagement Activity 2007
 
Description Speaker 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Health professionals
Results and Impact Presentation to clinicians on the role of IL-25 in asthma and allergy.

None as yet!
Year(s) Of Engagement Activity 2008
 
Description Work experience - school age 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Study participants or study members
Results and Impact School children attended for work experience.
Year(s) Of Engagement Activity 2016